Efficacy of cyclosporine eye drops in managing post-cataract surgery dry eye symptoms: A randomized controlled trial

Many patients develop dry eye symptoms or further exacerbation post-cataract surgery. The aim is to analyse the efficacy of cyclosporine A (CsA) eye drops on the dry eye symptoms post-cataract surgery (DEPC). 100 DEPC patients admitted to First Affiliated Hospital of Gannan Medical University from August 2022 to August 2024 were randomly divided into control group (n=50) and study group (n=50): The control group was treated with sodium vitrate eye drops, the study group was treated with CsA eye drops. The primary assessments were the ocular surface disease index questionnaire (OSDI): tear break-up time (TBUT) and schirmer I test (SIT). Secondary outcomes included visual acuity, tear inflammatory factors, clinical efficacy and adverse reaction incidence. Before medication, no remarkable difference of the both groups. TBUT, SIT and visual acuity were obviously improved, and the OSDI score and inflammatory factors were markedly decreased in the both groups after medication 1 week, 2 weeks and 1 month (P<0.05). The study group were superior to the control group (P<0.05). The study group’s clinical efficacy was above the control group, the adverse reaction incidence was below the control group (P<0.05). This treatment is accurate in its efficacy and has high clinical value.